Red flags include: Selling FDA-approved medications (semaglutide, tirzepatide) under research use disclaimers this practice is what triggered enforcement actions against multiple vendors Making health claims or dosing recommendations for human use Operating without a clear US business entity or verifiable address Prior FDA warning letters (publicly searchable on the FDA website) Vendors that have built their business model around regulatory gray areas are the most vulnerable to the continued enforcement actions that characterized 2025-2026

But in practice, and especially with regard to synthetic and recombinant peptide forms, there are some considerable potential safety concerns: Immunogenicity Most notably, per a 2020 assessment on therapeutic peptide safety, synthetic and recombinant peptides pose the risk of immunogenicity the ability of a substance to provoke an immune response.15 An immunogenicity-inducing peptide, when introduced to the body, would cause the bodys immune system to perceive the peptide not as a medication but as a threat
Acute Gallbladder Disease: Tirzepatide may cause gallbladder problems, including gallstones
Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil
These testing conditions are highly demanding and far exceed the typical conditions encountered during standard courier shipping
PLoS Genet